Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2175

3.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
4.
5.

The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.

Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.

Cancer Gene Ther. 2000 Dec;7(12):1543-56.

7.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
8.

Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.

Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, McEarchern JA, Akporiaye ET.

Cancer Immunol Immunother. 2001 Jul;50(5):229-40.

PMID:
11499806
10.

Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.

Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hibino H, Wu MS, Izawa K, Hamada H, Asano S.

Cancer Gene Ther. 1998 Jan-Feb;5(1):29-37.

PMID:
9476964
11.

Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.

Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S.

Cancer Res. 2004 Mar 1;64(5):1867-74.

12.

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.

Comes A, Rosso O, Orengo AM, Di Carlo E, Sorrentino C, Meazza R, Piazza T, Valzasina B, Nanni P, Colombo MP, Ferrini S.

J Immunol. 2006 Feb 1;176(3):1750-8.

13.

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.

15.

Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.

Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.

Cancer Res. 2003 Nov 15;63(22):7920-5.

17.
18.

Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.

Cancer Res. 2006 Jan 15;66(2):1147-54.

19.
20.

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL.

J Exp Med. 2001 Nov 5;194(9):1195-205.

Supplemental Content

Support Center